Jorge Gómez-Miragaya

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8043520/publications.pdf

Version: 2024-02-01

1478280 1872570 6 205 6 6 citations h-index g-index papers 6 6 6 496 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer. Oncogene, 2019, 38, 7106-7112.	2.6	48
2	The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. Molecular Cancer Research, 2019, 17, 2063-2076.	1.5	20
3	Chromosome 12p Amplification in Triple-Negative/ <i>BRCA1-</i> Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. Cancer Research, 2019, 79, 4258-4270.	0.4	17
4	Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+Tumor-Initiating Population. Stem Cell Reports, 2017, 8, 1392-1407.	2.3	62
5	Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer. Molecular and Cellular Oncology, 2017, 4, e1338208.	0.3	10
6	Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs. PLoS ONE, 2015, 10, e0131241.	1.1	48